United Therapeutics (UTHR) Other Accumulated Expenses (2009 - 2026)

United Therapeutics has disclosed Other Accumulated Expenses across 18 years of filings, most recently posting $100.8 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $100.8 million, down 34.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $100.8 million (down 34.76% YoY), and the FY2025 annual result was $72.6 million, down 22.44% from the prior year.
• Other Accumulated Expenses came in at $100.8 million for Q1 2026 at United Therapeutics, up from $72.6 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $154.5 million in Q1 2025 to a low of $32.5 million in Q4 2022.
• The 5-year median for Other Accumulated Expenses is $72.6 million (2025), against an average of $74.4 million.
• Across the five-year window, Other Accumulated Expenses plunged 36.51% in 2023 and jumped 227.2% in 2024, its largest moves.
• United Therapeutics' Other Accumulated Expenses stood at $32.5 million in 2022, then surged by 118.46% to $71.0 million in 2023, then surged by 31.83% to $93.6 million in 2024, then fell by 22.44% to $72.6 million in 2025, then surged by 38.84% to $100.8 million in 2026.
• The last three Other Accumulated Expenses figures came in at $100.8 million (Q1 2026), $72.6 million (Q4 2025), and $78.3 million (Q3 2025), per Business Quant data.